Low-Dose Calcium Noninferior for Reducing Risk of Preeclampsia

11 Jan 2024
Clinical ResultClinical Study
THURSDAY, Jan. 11, 2024 -- Low-dose calcium supplementation is noninferior to high-dose supplementation for reducing the risk of preeclampsia, according to a study published in the Jan. 11 issue of the New England Journal of Medicine.
Pratibha Dwarkanath, Ph.D., from St. John's Research Institute in Bangalore, India, and colleagues conducted two independent randomized trials of calcium supplementation in pregnancy in India and Tanzania to assess the noninferiority of a 500-mg daily dose to a 1,500-mg daily dose. The two primary outcomes in each trial were preeclampsia and preterm birth; the noninferiority margins for the relative risks were 1.54 and 1.16, respectively.
Each trial included 11,000 nulliparous pregnant women. The researchers found that the cumulative incidence of preeclampsia was 3.0 and 3.6 percent, respectively, in the 500- and 1,500-mg groups in the India trial (relative risk, 0.84; 95 percent confidence interval, 0.68 to 1.03), and 3.0 and 2.7 percent, respectively, in the Tanzania trial (relative risk, 1.10; 95 percent confidence interval, 0.88 to 1.36); these values were consistent with the noninferiority of the lower dose in both trials. The percentage of preterm births was 11.4 and 12.8 percent in the 500- and 1,500-mg groups, respectively, in India (relative risk, 0.89; 95 percent confidence interval, 0.80 to 0.98), which was within the noninferiority margin; the corresponding percentages were 10.4 and 9.7 percent in the Tanzania trial (relative risk, 1.07; 95 percent confidence interval, 0.95 to 1.21), which exceeded the noninferiority margin.
"The 500-mg dose that we studied as a comparator reduces the pill burden and would be expected to reduce program costs," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.